A roundup of the most newsworthy healthcare press releases from PR Newswire, including new company mergers, Alzheimer's ...

NEW YORK, Dec. 5, 2025 /PRNewswire/ -- With thousands of press releases published each month, it can be difficult to keep up ...

The FDA agreed with Vanda's position that motion sickness is an acute, self-limiting physiologic response rather than a chronic or chronic-intermittent condition. The Agency there ...

A millionaire developer has won a legal stoush with council to swing a wrecking ball at his $8m “magnificent estate” which ...

Tradipitant could become the first new pharmacologic treatment for motion sickness in over 40 years.

FDA accelerates re-review of Vanda's tradipitant and begins label talks, keeping its motion sickness drug on track for key 2025 decisions.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced the following updates regarding tradipitant for motion ...

Vanda Pharmaceuticals stands at a pivotal point, leveraging strong Fanapt growth and a robust late-stage pipeline for future expansion. VNDA's aggressive investment in commercial infrastructure has ...

Overview: Vanda Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies for high unmet medical needs globally, with a market cap of approximately $303.76 million ...

Shares of Vanda Pharmaceuticals rose after a study evaluating its treatment to prevent side effects from weight-loss drug Wegovy met its primary endpoint. The stock climbed 18%, to $5.20, late Tuesday ...

Vanda Pharmaceuticals (VNDA) delivered its third quarter 2025 earnings report, highlighting 18% revenue growth and strong Fanapt sales. The company also refined its revenue outlook while advancing key ...

Vanda Pharmaceuticals ((VNDA)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...